Article

DIA-based Proteomics Identifies IDH2 as a Targetable Regulator of Acquired Drug Resistance in Chronic Myeloid Leukemia

2021-04-09

Abstract excerpt

Drug resistance is a critical obstacle to effective treatment in patients with chronic myeloid leukemia (CML). To understand the underlying resistance mechanisms in response to imatinib (IMA) and adriamycin (ADR), the parental K562 cells were treated with low doses of IMA or ADR for two months to generate derivative cells with mild, intermediate and severe resistance to the drugs as defined by their increasing res...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: cf1b4bc9-4e41-5865-be35-4b5ced0ad094
DOI: 10.1101/2021.04.08.438976

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

DIA-based Proteomics Identifies IDH2 as a Targetable Regulator of Acquired Drug Resistance in Chronic Myeloid LeukemiaDOI 10.1101/2021.04.08.438976Read

Resistance to mutant IDH inhibitors in acute myeloid leukemia: Molecular mechanisms and therapeutic strategies.Semantic proximity Read

LIN28A-Dependent Kinome and Phosphoproteome Reprogramming Promotes Imatinib ResistanceSemantic proximity Read

[Performing integrative transcriptomic and chemical screening to identify patient-specific vulnerabilities in poor-prognosis acute myeloid leukemia].Semantic proximity Read

Identification of chemoresistance-related cell-surface glycoproteins in leukemia cells and functional validation of candidate glycoproteins.Semantic proximity Read

Targeting DESI2 as a Novel Therapeutic Strategy for JAK2-Mutant Leukemias.Semantic proximity Read

Multi-omic profiling of tyrosine kinase inhibitor-resistant K562 cells suggests metabolic reprogramming to promote cell survivalSemantic proximity Read

A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patientsSemantic proximity Read

Utilizing proteomics and phosphoproteomics to predict <i>ex vivo</i> drug sensitivity across genetically diverse AML patientsSemantic proximity Read

Identification of common genes and pathways underlying imatinib and nilotinib treatment in CML: a Bioinformatics StudySemantic proximity Read

Isocitrate dehydrogenase 2 mutation promotes cytarabine resistance in acute myeloid leukemia by Warburg effect.Semantic proximity Read

Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid LeukemiaSemantic proximity Read

Biased random walk model for the prioritization of drug resistance associated proteinsSemantic proximity Read